Table 2.
Efficacy (HbA1c [%]) by Homa IR, BMI, T2DM duration and duration of metformin use
| Vilda 50 mg b.i.d. + metformin | SU + metformin | |||
|---|---|---|---|---|
| BL | Mean ∆ | BL | Mean ∆ | |
| BL Homa IR | ||||
| n | 1,507 | 1,237 | ||
| <5 (mean = 2.8/2.7) | 7.63 ± 0.02 | −0.65 ± 0.02* | 7.51 ± 0.03 | −0.76 ± 0.02* |
| n | 598 | 428 | ||
| ≥5 (mean = 8.6/8.3) | 8.07 ± 0.05 | −0.68 ± 0.04* | 7.80 ± 0.05 | −0.77 ± 0.05* |
| BL BMI | ||||
| n | 444 | 398 | ||
| <27 kg/m2 (mean = 24.9/25.1) | 7.80 ± 0.05 | −0.67 ± 0.04* | 7.66 ± 0.05 | −0.80 ± 0.04* |
| n | 556 | 453 | ||
| ≥27 to <30 kg/m2 (mean = 28.5/28.4) | 7.74 ± 0.04 | −0.67 ± 0.04* | 7.59 ± 0.04 | −0.79 ± 0.04* |
| n | 1,446 | 1,106 | ||
| ≥30 kg/m2 (mean = 35.3/35.1) | 7.72 ± 0.03 | −0.63 ± 0.02* | 7.58 ± 0.03 | −0.73 ± 0.03* |
| BL T2DM duration | ||||
| n | 236 | 198 | ||
| 0 to <1 year (mean = 0.6/0.6) | 7.47 ± 0.06 | −0.64 ± 0.05* | 7.32 ± 0.06 | −0.73 ± 0.06* |
| n | 1,061 | 829 | ||
| ≥1 to <5 years (mean = 2.9/2.9) | 7.65 ± 0.03 | −0.60 ± 0.03* | 7.49 ± 0.03 | −0.71 ± 0.03* |
| n | 1,155 | 936 | ||
| ≥5 years (mean = 9.7/9.8) | 7.88 ± 0.03 | −0.69 ± 0.03* | 7.75 ± 0.03 | −0.80 ± 0.03* |
| BL duration of metformin use | ||||
| n | 709 | 580 | ||
| 0 to <1 year (mean = 0.6/0.6) | 7.70 ± 0.04 | −0.63 ± 0.03* | 7.53 ± 0.04 | −0.75 ± 0.04* |
| n | 1,274 | 1,022 | ||
| ≥1 to <5 years (mean = 2.6/2.6) | 7.70 ± 0.03 | −0.63 ± 0.02* | 7.58 ± 0.03 | −0.74 ± 0.03* |
| n | 468 | 361 | ||
| ≥5 years (mean = 7.9/7.7) | 7.93 ± 0.05 | −0.70 ± 0.04* | 7.76 ± 0.05 | −0.82 ± 0.05* |
Data are mean ± SE
b.i.d. twice daily, BL baseline, BMI body mass index, HbA 1c hemoglobin A1c, Mean ∆ mean change from BL, n number of patients with observations at both baseline and endpoint, SU sulfonylurea, T2DM type 2 diabetes mellitus, Vilda vildagliptin
* P < 0.0001